Comprehensive repository of peer-reviewed clinical trials and preclinical publications investigating Tirzepatide.
Obesity is a chronic disease contributing to substantial morbidity. In this phase 3 double-blind, randomized, controlled trial, 2,539 adults with a BMI >= 30 were assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks.
In this open-label, 40-week, phase 3 trial, 1,879 patients with type 2 diabetes were randomly assigned in a 1:1:1:1 ratio to receive subcutaneous tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg once weekly. The primary endpoint was the change in glycated hemoglobin level from baseline to 40 weeks. All three doses of tirzepatide demonstrated statistically superior reductions in HbA1c and greater reductions in body weight compared to semaglutide 1 mg.
